about
sameAs
Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancerFormative research on perceptions of biobanking: what community members thinkHelicobacter pylori-induced alteration of epithelial cell signaling and polarity: a possible mechanism of gastric carcinoma etiology and disparityPaving the Way to Personalized Genomic Medicine: Steps to Successful Implementation.Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profilingCo-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular eraImplementing personalized medicine in a cancer centerPrognostic Fifteen-Gene Signature for Early Stage Pancreatic Ductal AdenocarcinomaModels for prevention and treatment of cancer: problems vs promises.Personalized medicine in oncology: tailoring the right drug to the right patient.Drug development and clinical trials--the path to an approved cancer drug.(99m)Tc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials.Discordance of Somatic Mutations Between Asian and Caucasian Patient Populations with Gastric Cancer.The development of composite circulating biomarker models for use in anticancer drug clinical development.12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?[Clinical and health economic challenges of personalized medicine].
P2860
Q28394974-B98BB657-DD66-46AE-AEF1-FB62E755A426Q28686910-864516CD-5BE4-407F-A8A9-EE0FB7F08454Q30412040-62FBEB31-6F74-43C8-94C5-DDE4F21F0316Q33602704-F23973DD-B22C-4814-94EF-0947EA35BD54Q35070183-1E4C40EA-B765-4A68-92D0-32708175E6E1Q35606544-B7259698-7E71-40FE-B5B6-5E38AB6E752EQ35619239-34F2ACDF-195B-4C9E-8794-51CA7D19FB20Q35738659-14762AA4-1467-4AD4-B6D2-3897F3527EACQ37356273-0CDAEF79-25E4-4E0C-B230-8BBB6121AE8CQ37779306-A7539A8A-52BA-44AC-9909-B014D4E2ABD0Q37988792-F921A0AE-3BD0-439A-B17C-C55D61F32AB0Q38566895-E41A2BF7-4368-49FE-B388-661A3534D08CQ39048329-225CAA2F-9B48-461D-9926-E9DAE39A24B5Q39863702-B1DD693D-881E-4F7B-9C48-CA2F3DE93A8EQ41883987-2B838EB3-B85B-498E-971A-C0E609D75A24Q52888617-3A333B7C-481D-4B93-9001-1D7DE2B04796
P2860
description
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2008
@ast
scientific article (publication date: 15 September 2008)
@en
vedecký článok (publikovaný 2008/09/15)
@sk
vědecký článek publikovaný v roce 2008
@cs
wetenschappelijk artikel (gepubliceerd op 2008/09/15)
@nl
wissenschaftlicher Artikel
@de
наукова стаття, опублікована у вересні 2008
@uk
مقالة علمية (نشرت في 15-9-2008)
@ar
name
On the eve of personalized medicine in oncology
@ast
On the eve of personalized medicine in oncology
@en
On the eve of personalized medicine in oncology
@nl
type
label
On the eve of personalized medicine in oncology
@ast
On the eve of personalized medicine in oncology
@en
On the eve of personalized medicine in oncology
@nl
prefLabel
On the eve of personalized medicine in oncology
@ast
On the eve of personalized medicine in oncology
@en
On the eve of personalized medicine in oncology
@nl
P2093
P1433
P1476
On the eve of personalized medicine in oncology
@en
P2093
Dan Sullivan
James Mule
Timothy J Yeatman
William S Dalton
P2860
P304
P356
10.1158/0008-5472.CAN-08-1374
P407
P577
2008-09-15T00:00:00Z